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Abstract
Background: Intramyocellular lipid accumulation is strongly related to insulin resistance in humans, and we have shown
that high glucose concentration induced de novo lipogenesis and insulin resistance in murin muscle cells. Alterations in Wnt
signaling impact the balance between myogenic and adipogenic programs in myoblasts, partly due to the decrease of
Wnt10b protein. As recent studies point towards a role for Wnt signaling in the pathogenesis of type 2 diabetes, we
hypothesized that activation of Wnt signaling could play a crucial role in muscle insulin sensitivity.
Methodology/Principal Findings: Here we demonstrate that SREBP-1c and Wnt10b display inverse expression patterns
during muscle ontogenesis and regeneration, as well as during satellite cells differentiation. The Wnt/b-catenin pathway was
reactivated in contracting myotubes using siRNA mediated SREBP-1 knockdown, Wnt10b over-expression or inhibition of
GSK-3b, whereas Wnt signaling was inhibited in myoblasts through silencing of Wnt10b. SREBP-1 knockdown was sufficient
to induce Wnt10b protein expression in contracting myotubes and to activate the Wnt/b-catenin pathway. Conversely,
silencing Wnt10b in myoblasts induced SREBP-1c protein expression, suggesting a reciprocal regulation. Stimulation of the
Wnt/b-catenin pathway i) drastically decreased SREBP-1c protein and intramyocellular lipid deposition in myotubes; ii)
increased basal glucose transport in both insulin-sensitive and insulin-resistant myotubes through a differential activation of
Akt and AMPK pathways; iii) restored insulin sensitivity in insulin-resistant myotubes.
Conclusions/Significance: We conclude that activation of Wnt/b-catenin signaling in skeletal muscle cells improved insulin
sensitivity by i) decreasing intramyocellular lipid deposition through downregulation of SREBP-1c; ii) increasing insulin
effects through a differential activation of the Akt/PKB and AMPK pathways; iii) inhibiting the MAPK pathway. A crosstalk
between these pathways and Wnt/b-catenin signaling in skeletal muscle opens the exciting possibility that organ-selective
modulation of Wnt signaling might become an attractive therapeutic target in regenerative medicine and to treat obese
and diabetic populations.
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Introduction
The first suggestion for a role of Wnt signaling in the
pathogenesis of type 2 diabetes came from a study which reported
a single nucleotide polymorphism locus in the Wnt5b gene that
confered susceptibility to type 2 diabetes in a Japonese population
[1]. More recently, variants of the transcription factor TCF7L2, a
component of the Wnt/b-catenin pathway, were shown to be
involved in b-cell dysfunction and the etiology of type 2 diabetes
[2]. In addition, a link between cellular glucose sensing and the
Wnt/b-catenin pathway was recently reported in macrophages
[3], indicating that this pathway could be inappropriately activated
in diabetic hyperglycemic or obese subjects. These results strongly
suggest that Wnt signaling could be involved in the regulation of
glucose homeostasis in different organs, particularly in insulin-
responsive tissues such as skeletal muscle.
The Wnt/b-Catenin Signaling Pathway
A central feature of the canonical Wnt/b-catenin pathway is the
regulation of cytosolic b-catenin protein levels via a destruction
complex containing glycogen synthase kinase-3b (GSK-3b),
adenomatous polyposis coli (APC) and axin. In the absence of
Wnt signals, b-catenin is targeted for ubiquitin-mediated degra-
dation [4]. Binding of Wnt ligands to a Frizzled/LRP receptor
complex leads to the inactivation of GSK-3b and accumulation of
cytosolic b-catenin. Then b-catenin translocates into the nucleus
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transcription of Wnt-responsive genes involved in cell proliferation
(cyclin D1, myf5) and differentiation [5,6]. Wnt signaling also
plays a key role in adult tissues homeostasis by determining
differentiating cell fate and maintaining stem cell pluripotency [7].
Shift in Lipid Metabolism and Muscle Insulin Resistance
Several tissues, including skeletal muscle, display with ageing an
adverse shift in lipid metabolism which contributes to insulin
resistance and type 2 diabetes [8]. Insulin resistance has been
linked to the accumulation of intramyocellular lipids in skeletal
muscle of diabetic patients [9,10] in relation with the lipogenic
transcription factor SREBP-1c which mediates insulin’s actions on
hepatic [11,12,13] and skeletal muscle gene expression in humans
[14] and rodents [15]. We have shown that adenoviral delivery of
SREBP-1 gene to cultured rat muscle satellite cells resulted in a
gene expression profile that would suppress fat oxidation and
promote intramyocellular lipid accumulation [15], suggesting that
SREBP-1c plays a role in the development and/or maintenance of
skeletal muscle insulin resistance.
Role of Wnt Signaling in the Balance Adipogenesis/
Myogenesis
Down-regulation of Wnt signaling may alter myoblastic
differentiation potential as a function of age, as it controls the
balance between myogenic and adipogenic potential in myoblasts
[16], suggesting that endogenous Wnt signaling inhibits adipo-
genesis [17]. Although myoblast determination and differentiation
are regulated by myogenic transcription factors (myf5, myoD,
myogenin) [18], their activity can be overcome in vitro so that
myoblasts can be induced to transdifferentiate into adipocyte-like
cells by treatment with thiazolidinediones, potent activators of
PPAR-c [19,20], or high glucose concentration [21]. These results
strongly suggest that skeletal muscle satellite cells are able to enter
an adipogenic program under particular pathophysiological
conditions.
We have shown previously that high glucose concentration up-
regulated SREBP-1c in cultured muscle satellite cells, leading to de
novo lipogenesis and insulin resistance [15]. Here we show a
reciprocal regulation between SREBP-1c and Wnt10b mRNA and
protein expression in muscle cells, in relation with intramyocellular
lipid deposition and insulin resistance. Surprisingly, stimulation of
the Wnt/b-catenin pathway through SREBP-1c knockdown,
GSK-3b inhibition or Wnt10b over-expression prevented intra-
myocellular lipid synthesis, redirected myotubes toward a
myogenic phenotype and restored insulin sensitivity in insulin-
resistant myotubes through a molecular mechanism involving a
differential activation of Akt/PKB and AMPK pathways.
Results
SREBP-1c and Wnt10b Proteins Show an Inverse
Expression Pattern In Vivo
Figure 1A represents the evolution of SREBP-1c and Wnt
proteins that are expressed during skeletal muscle ontogenesis.
Wnt3 protein was strongly expressed in hind limb muscles of rat
fetuses, but was rapidly down-regulated after birth, whereas
Wnt5a and Wnt7 were not detected (result not shown). In contrast,
Wnt10b protein was barely detectable in fetal muscles, but was
strongly up-regulated after birth and remained elevated in
newborn muscles throughout suckling. Then it decreased
drastically after weaning to become quite undetectable in adult
muscles. Conversely, SREBP-1c protein was not expressed in
muscles from birth to weaning while Wnt10b protein level was
elevated. After weaning, SREBP-1c precursor and mature forms
increased by 5-fold when muscle growth was over, as shown by a
strong expression of the fast Myosin Heavy Chain-2 protein
(MyHC-2). These results suggest that Wnt10b protein could be
only expressed in myoblasts that are involved in postnatal skeletal
muscle growth, a period during which the lipogenic factor
SREBP-1c is not detected.
To challenge this hypothesis, we assessed the differential
expression of Wnt10b and SREBP-1c proteins during skeletal
muscle regeneration in adult EDL muscles. EDL muscle from the
left hind limb was crushed using tweezers as previously described
[22] and the non-injured contralateral EDL was taken as a
control. Two days after crush injury, Wnt10b protein levels
increased dramatically and remained elevated until 8 days
following the injury, then became undetectable after 30 days
when regeneration was over. Myogenin was transiently up-
regulated during the regeneration process, whereas SREBP-1c
was completely down-regulated (Figure 1B). These findings suggest
that Wnt10b might activate a signaling pathway that prevents the
expression of lipogenic factors during skeletal muscle growth and
regeneration.
SREBP-1c and Wnt10b Show an Inverse Expression
Pattern in Cultured Satellite Cells
As muscle growth and regeneration occur through the
activation of satellite cells, we studied the expression of Wnt10b
protein in primary cultures of satellite cells isolated from hind limb
muscles. Myoblasts were allowed to proliferate for 5 days, then
fusion was induced and spontaneously contracting myotubes were
obtained at day 9. Wnt10b protein was strongly expressed in
proliferating myoblasts, then decreased during cell fusion and was
no longer detectable in contracting myotubes (Figure 2A), whereas
Wnt3 protein expression remained almost unchanged. In contrast,
Wnt10b down-regulation was concomitant with the up-regulation
of SREBP-1c and fatty acid synthase (FAS) proteins, showing that
lipogenesis was active in contracting myotubes (Figure 2A). These
results demonstrated that Wnt10b and SREBP-1c proteins
adopted inverse expression patterns according to the differentia-
tion stage of myogenic cells.
Wnt10b Silencing Increases SREBP-1c mRNA Expression
in Myoblasts
To determine whether Wnt10b knockdown could induce
SREBP-1c expression, myoblasts were transfected with a mix of
3 specific Wnt10b siRNAs or with a control scrambled siRNA. In
parallel, myotubes were transfected with a vector containing
mouse Wnt10b cDNA. Total RNA was extracted 48 hours after
transfection and semi-quantitative PCR was performed. Wnt10b
knockdown was sufficient to induce SREBP-1c mRNA expression
in myoblasts, whereas Wnt10b over-expression drastically de-
creased SREBP-1c mRNA expression in myotubes (Figure 2B).
Furthermore, Wnt10b knockdown increased by 3-fold PPAR-c
mRNA expression in myoblasts, whereas Wnt10b over-expression
decreased PPAR-c mRNA in myotubes. In contrast, PPAR-b and
MyHC-2 mRNAs were unaffected. These results show that
Wnt10b decreased SREBP-1c and PPAR-c expression at the
transcriptional level.
SREBP-1c Silencing Activates the Wnt/b-Catenin Pathway
in Contracting Myotubes
In order to determine whether SREBP-1c could inhibit Wnt10b
expression, myotubes were transfected with a SREBP-1 siRNA
duplex or with a control scrambled siRNA, and total proteins were
Wnt Signaling in Muscle
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in siRNA-transfected myotubes as compared with control
myotubes, indicating a knockdown efficiency of more than 90%.
Gene silencing was successful even in the presence of 10 nM
insulin, a potent activator of SREBP-1c transcription. Surprisingly,
SREBP-1c knockdown was sufficient to induce Wnt10b protein
expression in contracting myotubes, particularly in the presence of
insulin (Figure 2C). To determine whether SREBP-1c knockdown
stimulated Wnt/b-catenin signaling, the activity of GSK-3b was
checked using an antibody raised against phosphorylated GSK-
Figure 1. Differential expression of SREBP-1c and Wnt proteins during skeletal muscle ontogenesis and regeneration. (A) Western
blot analysis showing inverse expression patterns between Wnt10b and SREBP-1c during ontogenesis. The developmental stages are underlined
using antibodies against developmental (MyHC-Dev) and fast (MyHC-2) myosin heavy chains. (B) Western blot analysis of Wnt10b and SREBP-1c
protein levels in regenerating (R) adult EDL muscles at 2, 8, and 30 days after crush injury as compared to contralateral control (C) EDL. The down-
regulation of SREBP-1c was concomitant with the up-regulation of Wnt10b throughout regeneration. The blots are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0008509.g001
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PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8509Figure 2. Wnt10b and SREBP-1c are also inversely expressed in cultured satellite cells. (A) Western blot analysis showing an inverse
expression pattern between Wnt10b and SREBP-1c proteins according to the differentiation stage. In contrast, Wnt3 remained almost unchanged
throughout differentiation. SREBP-1c induced the up-regulation of the lipogenic enzyme FAS in myotubes. (B) Wnt10b knockdown was sufficient to
up-regulate SREBP-1c and PPARc mRNAs, whereas Wnt10b over-expression down-regulated their expression. RT-PCR was performed on myoblasts
transfected with a scrambled siRNA (lane 1), a pool of 3 Wnt10b siRNAs (lane 2), or a plasmid encoding the mouse Wnt10 cDNA (lane 3) as described
in Material and Methods. (C) SREBP-1 knockdown stimulated Wnt signaling in contracting myotubes. Myotubes were transfected with SREBP-1
siRNAs or a scrambled siRNA, then treated or not with 10 nM insulin for 24 hours. SREBP-1 knockdown was sufficient to induce Wnt10b protein
expression in myotubes, particularly in the presence of insulin, and to activate the Wnt/b-catenin pathway, as shown by GSK-3b and b-catenin
activities. (D) Wnt10b knockdown induced SREBP-1c protein expression in myoblasts. Myoblasts were transfected with 30 pmoles or 60 pmoles of a
pool of 3 Wnt10b siRNAs, or with a scrambled siRNA as a control. Silencing Wnt10b was sufficient to induce SREBP-1c protein expression in myoblasts
through the inhibition of Wnt/b-catenin signaling. The blots are representative of 3 independent experiments.
doi:10.1371/journal.pone.0008509.g002
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Y216 which is active when phosphorylated, but is inactive when
dephosphorylated in response to Wnt/b-catenin signaling [23].
GSK-3b activity decreased by 3-fold in SREBP-1c knocked-down
myotubes. Furthermore, the dephosphorylated active form of b-
catenin was increased in these cells, while total GSK-3b and total
b-catenin remained unchanged. MyHC-2 level showed that
myotubes remained terminally differentiated after SREBP-1c
knockdown (Figure 2C). Taken together, these results suggest that
SREBP-1c could be involved in the down-regulation of Wnt
signaling which is observed in contracting myotubes.
Wnt10b Silencing Induces SREBP-1c Protein Expression in
Myoblasts
We wanted to determine whether Wnt10b knockdown could
conversely inducetheexpression of SREBP-1c proteininmyoblasts.
Total protein was extracted 48 hours after transfection of myoblasts
witha mix of 3 specific Wnt10bsiRNAs or with a control scrambled
siRNA. Wnt10b knockdown was sufficient to induce 24 hours later
SREBP-1c protein expression in myoblasts. The concomitant 2 to
3-fold increase in GSK-3b
Y216 phosphorylation led to the down-
regulation of active b-catenin in transfected myoblasts, showing an
inhibition of the Wnt/b-catenin pathway (Figure 2D).
Forced-Expression of Wnt10b Down-Regulates SREBP-1c
in Contracting Myotubes
In order to determine whether the over-expression of Wnt10b
could be sufficient to down-regulate SREBP-1c in myotubes, cells
were transfected with a plasmid encoding mouse Wnt10b cDNA,
and cytosolic and nuclear proteins were extracted 48 hours later.
Wnt10b over-expression was sufficient to totally abrogate the
expression of the cytoplasmic-precursor and nuclear-active forms
of SREBP-1c, even in the presence of insulin (Figure 3A). As
expected, Wnt10b over-expression decreased GSK-3b activity by
dephosphorylating Y
216 and induced the nuclear translocation of
active b-catenin, which led to the up-regulation of MyoD in the
nucleus. These results demonstrate that the reactivation of the
Wnt/b-catenin pathway down-regulated the lipogenic factor
SREBP-1c, but also stimulated the myogenic pathway in
contracting myotubes. Altogether, our data suggest that the
reciprocal regulation between SREBP-1c and Wnt10b resulted
from a crosstalk between Wnt/b-catenin signaling and the
transcription factor SREBP-1c.
Activation of the Wnt/b-Catenin Pathway Down-
Regulates SREBP-1c in Myotubes
Myotubes were treated for 48 hours with 6-BromoIndirubin-39-
Oxime (BIO), a selective inhibitor of GSK-3 activity that activates
the Wnt/b-catenin pathway [24]. BIO decreased GSK-3b activity
by preventing Y
216 phosphorylation (Figure 3B), but had no effect
on S
9 phosphorylation. As expected, the inhibition of GSK-3b up-
regulated the active form of b-catenin, resulting in SREBP-1c
down-regulation. These results show that reactivation of the Wnt/
b-catenin pathway whatever the technique used (SREBP-1c
knockdown, Wnt10b over-expression or selective GSK-3b inhibi-
tion) drastically diminished the lipogenic factor SREBP-1c in
contracting myotubes.
BIO Abolishes Glucose-Induced Intramyocellular Lipid
Accumulation in Myotubes
In myotubes cultured under physiological glucose concentration
(5 mM), few lipid droplets were detected using Oil Red O staining
(Figure 4A), whereas high glucose concentration (25 mM)
drastically increased SREBP-1c-mediated de novo lipogenesis
(Figure 4B), confirming what we have previously reported [25]. In
contrast, no intramyocellular lipids were detected in myotubes
treated with 1 mM BIO (Figure 4C). In addition, BIO was able to
induce the formation of terminally-differentiated contracting
myotubes, as the contractile apparatus was visible and nuclei
appeared in a peripheral position (Figure 4F). Thus, activation of
Wnt/b-catenin signaling redirected muscle cells toward the
myogenic pathway.
Effect of Wnt Signaling on 2-Deoxyglucose Transport in
Contracting Myotubes
As glucose transport reflects insulin sensitivity in skeletal muscle,
H
3-2-Deoxyglucose (2-DG) uptake was measured in contracting
myotubes. Myotubes cultured under physiological glucose con-
centration (G5) showed high insulin sensitivity, as 10 nM insulin
induced within 30 minutes a 2-fold increase in 2-deoxyglucose
uptake. Surprisingly, BIO treatment or Wnt10b over-expression
increased basal 2-deoxyglucose uptake by 30% and 40%
respectively, whereas uptake in the presence of BIO and insulin
was similar to insulin-stimulated uptake (Figure 5A, left panel). In
contrast, myotubes cultured for 48 hours in high glucose
concentration (G25) presented a drastic insulin-resistance, as
insulin was unable to stimulate 2-deoxyglucose uptake. However,
BIO or Wnt10b over-expression increased basal glucose uptake by
20% and 40%, respectively, and restored insulin sensitivity in these
myotubes (Figure 5A, right panel). Thus, the activation of Wnt
signaling had no effect on insulin-stimulated glucose uptake in
insulin-sensitive conditions, but increased glucose transport
independent of insulin and restored insulin sensitivity in insulin-
resistant myotubes.
BIO Induces GLUT4 Translocation
In skeletal muscle, glucose transport is carried out by the insulin-
sensitive glucose transporter GLUT4. In myotubes cultured in G5,
insulin induced GLUT4 translocation to the plasma membrane
within 30 minutes (Figure 5B). In contrast, insulin did not induce
GLUT4 translocation in myotubes cultured in G25, confirming a
strong insulin resistance. Surprisingly, BIO per se induced GLUT4
translocation to the plasma membrane in G25-cultured myotubes,
and insulin had an additive effect. This effect was specific for
GLUT4, as GLUT1 was unaffected (Figure 5B, Figure 5C). This
experiments showed that activation of Wnt/b-catenin signaling
induced GLUT4 translocation to the plasma membrane through
an insulin independent pathway.
Effect of BIO on GSK-3b Activity
In order to decipher the signaling pathways involved in BIO
effects, we performed time-course experiments in myotubes
cultured in G5 or G25. Within 30 minutes, BIO decreased
GSK-3b activity, as assessed by Y
216 phosphorylation, and
maximal inhibition (70% and 60% in myotubes cultured in G5
and G25 respectively) was observed after about 4 hours, then
remained for 12 hours in both cases. In contrast, BIO had no
significant effect on GSK-3b
S9 phosphorylation (Figure 6A).
Effect of BIO on Akt Signaling
Akt/PKB is a protein kinase activated by insulin and various
growth factors through pathways involving PI3 kinase. Akt1 is
activated by activation-loop phosphorylation at T
308 by the
pyruvate dehydrogenase kinase 1 (PDK1) [26], and Akt2 by
phosphorylation within the carboxy terminus at S
473 by mTor
[27]. Our data show in myotubes cultured in G5 that BIO
increased PDK1
S241 autophosphorylation within 30 minutes,
Wnt Signaling in Muscle
PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8509which induced Akt1
T308 phosphorylation for 8 hours, but had no
effect on Akt2
S473 phosphorylation. Finally the Akt substrate
AS160 (a Rab-GAPase involved in GLUT4 translocation) was
activated by phosphorylation on S
588 for at least 24 hours
(Figure 6B, left panel). In contrast, Akt1
T308 and AS160
S588 were
already highly phosphorylated in myotubes cultured in G25.
Surprisingly, the first effect of BIO was to bring the phosphor-
ylation state back to a basal level within 30 min. Then BIO up-
regulated Akt1
T308 and AS160
S588 phosphorylations that re-
mained elevated until 8 hours after BIO addition (Figure 6B, right
panel). These results could explain how BIO induced GLUT4
translocation and increased glucose uptake in myotubes that were
either sensitive or resistant to insulin action.
Effect of BIO on AMP Kinase Signaling
AMPK promotes GLUT4 translocation and glucose uptake in
skeletal muscle by a signaling cascade independent of the classical
insulin-PI3K-Akt pathway [28]. Recently, Jensen et al [29]
showed that twitch-contraction stimulated glucose uptake through
the activation of AMPK-a1 (but not AMPK-a2) independently of
Figure 3. Activation of Wnt signaling in contracting myotubes. (A) Over-expression of Wnt10b cDNA down-regulated SREBP-1c protein.
Myotubes were transfected with a plasmid encoding the mouse Wnt10b cDNA, then treated or not with 10 nM insulin for 24 hours. Western blot
analysis of cytoplasmic (left panel) and nuclear (right panel) protein extracts showing the down-regulation of precursor and mature forms of SREBP-1c
following the activation of the Wnt/b-catenin pathway. Wnt10b over-expression induced the nuclear accumulation of active b-catenin and MyoD.
Blots were normalized using antibodies raised against the cytoplasmic protein GAPDH or the nuclear protein Lamin A/C. (B) Myotubes were
submitted to a 48 hour-treatment with 1 mM BIO, then 10 nM insulin was added for 24 hours. BIO-mediated activation of the Wnt/b-catenin pathway
induced SREBP-1c down-regulation, even in the presence of insulin.
doi:10.1371/journal.pone.0008509.g003
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that BIO induced rapidly the phosphorylation of AMPK-a1o n
S
485, but had no effect on T
172 phosphorylation in myotubes
cultured in G5. In myotubes cultured in G25, AMPK-a1
S485
phosphorylation was 3-fold higher than in myotubes cultured in
G5. Addition of BIO down-regulated AMPK-a1
S485 phosphory-
lation to a basal level within 30 minutes, then AMPK-a1
S485 was
phosphorylated according to a time-course similar to the one
observed in myotubes cultured in G5 (Figure 6C).
Effect of BIO on MAP Kinase Signaling
As the MAP kinase (MAPK) pathway is involved in insulin
signal transduction, we wonder whether BIO, which was designed
as a specific GSK-3b inhibitor [30], could indirectly affect this
pathway. Figure 6D shows that the rapid (30 minutes) inhibition of
GSK-3b inhibited Erk1/2 phosphorylation after 1 hour, this effect
remaining for almost 12 hours in myotubes cultured in G5 or
G25. Taken together these results show that BIO induced, as a
downstream consequence of GSK-3b inactivation, the inhibition
of the MAP kinase pathway and the activation of Akt/PKB and
AMPK pathways in skeletal muscle cells.
Comparison between Insulin and BIO Signaling in
Contracting Myotubes
GSK-3b activity. Myotubes cultured either in G5 or G25 were
treated for 30 minutes with 10 nM insulin, and for 30 minutes or
1h o u rw i t h1mM BIO. Quantifications of western-blots show that
GSK-3b activity was inhibited in myotubes cultured in low or high
glucose concentration through either insulin-induced
phosphorylation of S
9, or BIO-induced dephosphorylation of Y
216
(Figure 7A).
Akt signaling. While insulin stimulated Akt2
S473 phosphoryla-
tion,BIOincreasedAkt1
T308phosphorylation(Figure7B),leadingto
AS160
S588 activation in myotubes cultured in G5 (Figure 7D). In
contrast, insulin did not stimulate Akt2
S473 phosphorylation in
myotubes cultured in G25, whereas BIO induced a biphasic
response: it first decreased Akt1
T308 and AS160
S588
phosphorylations to a basal level within 30 min, then reinduced
these phosphorylations (Figures 7B, 7D). These results show that
BIO is able to activate the Akt pathway in insulin-resistant myotubes
through a way different from the classical insulin/PI3K pathway.
AMPK signaling. Insulin had no effect on AMPK signaling in
myotubes cultured either in G5 or G25. In contrast, BIO induced
AMPK-a1
S485 phosphorylation whatever the glucose concentration,
but had no effect on AMPK-a
T172 phosphorylation. Thus, BIO
stimulated AMPK signaling through AMPK-a1
S485 phosphoryla-
tion (Figure 7C).
MAPK signaling. BIO and insulin had opposite effects on
MAPK signaling. BIO induced Erk1/2 dephosphorylation within
1 hour in myotubes cultured in G5 or G25, whereas insulin
increased Erk1/2 phosphorylation in myotubes cultured in G5,
but had no effect in myotubes cultured in G25 (Figure 7D).
Figure 4. Effect of BIO on intramyocellular lipid accumulation. Oil red O staining of intramyocellular lipids in myotubes cultured in 5 mM
glucose (A) 25 mM glucose (B) or 25 mM glucose in the presence of 1 mM BIO for 5 days (C). Phase-contrast microphotographs of the same
myotubes cultured in 5 mM glucose (D), or 25 mM glucose in the absence (E) or presence (F) of BIO. BIO totally abolished intramyocellular lipid
deposition. Scale bar 20 mm.
doi:10.1371/journal.pone.0008509.g004
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catenin pathway prevented an adipogenic phenotype and
improved insulin sensitivity in skeletal muscle cells through a
differential stimulation of the Akt and MAPK pathways.
Discussion
Our previous work demonstrated that high glucose concentra-
tion up-regulated SREBP-1c and insulin resistance in myotubes
Figure 5. Effect of Wnt signaling on glucose transport in contracting myotubes. (A) Myotubes cultured in 5 mM glucose (G5) or in 25 mM
glucose (G25) for 48 hours were transfected with a mouse Wnt10b cDNA or treated with 1 mM BIO. 2-deoxyglucose (2-DG) uptake was then
measured in the presence or absence of 10 nM insulin for 30 minutes as described in Material and Methods. Data are expressed as mean6SE from 5
independent experiments performed in triplicate. Significant difference from G5, (***) p,0.0001; (**) p,0.02; Significant difference from G25, (###)
p,0.0001; (##)p ,0.001. (B) BIO induced GLUT4 translocation to the plasma membrane. Myotubes were cultured in 5 mM (G5) or 25 mM glucose
(G25) for 48 hours in the presence or absence of 1 mM BIO. Myotubes were treated or not with 10 nM insulin for 30 minutes, then plasma membranes
were isolated. Western blot analysis showed that insulin and BIO induced GLUT4 translocation to the plasma membrane, whereas GLUT1 was
unaffected. (C) Quantification of GLUT4 and GLUT1 translocation. Data are expressed as mean6SE from 4 independent experiments. Significant
difference from G5, (***) p,0.0001; (**) p,0.01; (*) p,0.05.
doi:10.1371/journal.pone.0008509.g005
Wnt Signaling in Muscle
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inhibit adipogenic differentiation [32,33], we hypothesized that
Wnt10b normally represses the expression of lipogenic genes such
as SREBP-1c in skeletal muscle.
Wnt/b-Catenin Signaling Overcomes an Adipogenic
Program in Muscle
Here we show that Wnt10b was detected as long as SREBP-1c
was not present in growing muscles of suckling rats (Figures 1A,
2A). As SREBP-1c is sensitive to the nutritional status in skeletal
muscle [34], we cannot rule out a role for poly-unsaturated fatty
acids (PUFAs) which are abundant in mouse milk. Conversely, a
strong expression of SREBP-1c in adult muscle was concomitant
with the loss of Wnt10b. On the contrary, the regeneration process
reinduced Wnt10b protein expression and totally down-regulated
SREBP-1c in EDL muscle (Figure 1B). This is supported by the
observation that muscle regeneration was impaired in the Tibialis
Anterior of Wnt10b
2/
2 mice, where excessive lipid accumulation
occurred within activated satellite cells and regenerating myofibers
[35]. Thus, upon satellite cells activation, which started the
myogenic program, the lipogenic protein SREBP-1c remained
absent. These findings were confirmed in vitro as, whatever the
technique used (SREBP-1 knockdown, Wnt10b over-expression or
GSK-3b inbibition through BIO), activation of the Wnt/b-catenin
pathway decreased SREBP-1c mRNA and protein levels in
contracting myotubes. Conversely, silencing Wnt10b was sufficient
to increase SREBP-1c mRNA and protein as well as the
adipogenic phenotype of myoblasts, as shown by the up-regulation
of PPAR-c mRNAs.
These results suggest that activation of Wnt signaling overcame
an adipogenic program in muscle satellite cells. Such findings
could be very important in the general context of muscle
development, but also in the specific context of obesity and type
2 diabetes. In these pathologies, skeletal muscle has been observed
to have a reduced oxidative enzyme activity, increased glycolytic
activity, and increased lipid content. These metabolic character-
istics are related to skeletal muscle insulin resistance and are
Figure 6. Time-course of BIO effects on GSK-3b activity, Akt, AMPK and MAPK signaling in contracting myotubes. Myotubes were
cultured in 5 mM (G5) or 25 mM (G25) glucose concentration for 48 hours, then 1 mM BIO was added. Upper panels show western blots whereas
lower panels show quantifications of 3 to 5 independent experiments. (A) BIO decreased within 30 minutes GSK-3b
Y216 phosphorylation in myotubes
cultured either in G5 or G25, but had no effect on GSK-3b
S9 phosphorylation. (B) BIO induced PDK1
S241, Akt1
T308 and AS160
S588 phosphorylations, but
had no effect on Akt2
S473 phosphorylation in myotubes cultured either in G5 or G25. (C) BIO increased AMPK-a1
S485 phosphorylation, but had no
effect on AMPK-a
T172 phosphorylation in myotubes cultured in G5 (left panels). In contrast, BIO had a biphasic effect in myotubes cultured in G25:
AMPK-a1
S485 phosphorylation was decreased to a basal level within 30 minutes, then increased with a time-course similar to that observed in
myotubes cultured in G5 (right panels). (D) BIO decreased Erk1/2 phosphorylation with a similar time-course in myotubes cultured either in G5 or
G25. Data are expressed as mean6SE from 3 independent experiments.
doi:10.1371/journal.pone.0008509.g006
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glucose (G25) concentration were treated with 10 nM insulin for 30 minutes, or with 1 mM BIO for 30 and 60 minutes. (A) Insulin increased GSK-3b
S9
phosphorylation in myotubes cultured in G5 or G25, whereas BIO had no effect. In contrast, BIO decreased GSK-3b
Y216 phosphorylation, whereas
insulin had no effect. (B) Insulin increased Akt2
S473 phosphorylation in myotubes cultured in G5, whereas myotubes cultured in G25 were resistant to
insulin. BIO increased Akt1
T308 phosphorylation in myotubes cultured in G5, and had a biphasic effect in myotubes cultured in G25. (C) BIO stimulated
AMPK-a1
S485 but not AMPK-a2
T172 phosphorylation whatever the glucose concentration, whereas insulin had no effect on AMPK phosphorylation.
(D) In contrast to BIO, insulin failed to increase AS160
S588 phosphorylation. BIO showed a biphasic effect in myotubes cultured in G25. (E) Insulin
increased Erk1/2 phosphorylation only in myotubes cultured in G5, whereas BIO diminished Erk1/2 phosphorylation in myotubes whatever the
glucose concentration. Lower panels show quantifications of 3 independent experiments. Data are expressed as mean6SE. Significant difference
between BIO and insulin, (###)p ,0.001; (##)p ,0.01. Significant difference between control and insulin (***) p,0.001; (**) p,0.01. NS: non
significant.
doi:10.1371/journal.pone.0008509.g007
Wnt Signaling in Muscle
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8509factors potentially related to muscle fiber type [36], particularly for
fast MyHC-expressing fibers [31]. To address this important topic,
we are now studying the effects of direct electrotransfection of
Wnt10b and other Wnt factors in mouse Tibialis Anterior and
Soleus muscles on fiber-type composition, metabolism, intramyo-
cellular lipid content and insulin sensitivity.
Wnt10b and SREBP-1c Are Mutually Exclusive in Muscle
Wnt10b and BIO activate the Wnt/b-catenin pathway
through inactivation of GSK-3b
Y216 both in insulin-sensitive
and insulin-resistant myotubes (Figures 8a, 8b), which resulted in
nuclear translocation of active b-catenin, stimulation of myogenic
genes transcription (e.g myoD, myogenin) and inhibition of
Srebp-1c transcription (Figure 8f). In fact, three putative
consensus sequences for sterol regulatory elements (SRE) are
present in the Wnt10b promoter, and we have already shown
negative regulation by Srebp-1c on the mitochondrial uncoupling
protein, UCP3, in contracting myotubes [15]. On the other hand,
insulin resistance is accompanied by various degrees of impair-
ment of the PI3K signaling [37], whereas the MAPK pathway
does not appear defective in the state of insulin resistance [38]. In
skeletal muscle cells, insulin-induced Srebp-1c transcription was
shown to be mediated by the MAPK pathway, not by the PI3K
pathway [39]. In this case, insulin-stimulated expression of
SREBP-1c would remain intact in the insulin-resistant state
(Fig. 8-c), which could explain increased lipogenesis and
intramyocellular lipid deposition. In contrast, stimulation of the
Wnt/b-catenin pathway would inhibit the MAPK pathway in
insulin-sensitive and insulin-resistant myotubes as well, which
could explain the down-regulation of Srebp-1c expression
(Figure 8a, 8b). Nevertheless, the mechanism involved in the
reciprocal regulation of Wnt10b and Srebp-1c remains to be
elucidated at the transcriptional level.
Hypothesis for an Interplay between Wnt Signaling and
Insulin Sensitivity in Muscle Cells
Stimuli that induce GLUT4 translocation in skeletal muscle
include insulin via the PI3K pathway [40], hypoxia through nitric
Figure 8. Hypothesis for an interplay between insulin and BIO signaling in contracting myotubes. Wnt10b (a) and BIO (b) activate the
Wnt/b-catenin pathway through the inactivation of GSK-3b
Y216 phosphorylation, which results in the nuclear translocation of active b-catenin,
stimulation of myogenic genes transcription such as myoD, and inhibition of Srebp-1c transcription (f). Insulin-induced Srebp-1c transcription is
mediated by the MAPK pathway in muscle cells. BIO inhibits the MAPK pathway, which could explain the down-regulation of Srebp-1c gene
expression (c). In parallel, inactivation of GSK-3b
Y216 is followed by autophosphorylation of PDK1
S241 which phosphorylates Akt1
T308 (but not
Akt2
S473), then the subsequent phosphorylation of AS160
S588 induces GLUT4 translocation (e). In contrast, insulin stimulates GLUT4 translocation
through the PI3K/Akt2
S473/AS160 pathway (d). BIO activates the AMP kinase pathway by phosphorylating AMPK-a1
S485, which also induces GLUT4
translocation (e). These results strongly suggest that Wnt signaling, in contrast to insulin signaling, increases glucose transport in both insulin-
sensitive and insulin-resistant myotubes through the activation of AMPK-a1 and Akt2/AS160 pathways.
doi:10.1371/journal.pone.0008509.g008
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signaling [42]. Wnt signaling stimulated glucose transport
independent of insulin, but also restored insulin sensitivity in
insulin-resistant myotubes. Inactivation of GSK-3b
Y216 was
followed by the phosphorylation of Akt1
T308 by PDK1. Then
the subsequent phosphorylation of AS160
S588 induced GLUT4
translocation to the plasma membrane. We don’t know yet
whether BIO induced PDK1
S241 autophosphorylation through the
inhibition of GSK-3b
Y216 or via a pathway not yet defined
(Figure 8b). In fact, BIO was reported to be an inhibitor of GSK-
3a/b through interactions within the ATP binding pocket [30],
but also an inhibitor of PDK1 in silico at concentrations ranging
from 10 mMt o3 0mM [43]. In our study, BIO 1 mM was an
activator of PDK1 autophosphorylation in myotubes that were
either sensitive or resistant to insulin. Insulin-induced GLUT4
translocation was reported to occur through a pathway involving
IRS1/PI3K/PDK2/Akt2
S473/AS160 in human skeletal muscle
[44], and our results show that insulin stimulated a similar
pathway in insulin-sensitive myotubes (Figure 8d). In addition,
BIO activated the AMPK pathway by phosphorylating AMPK-
a1
S485, but not AMPK-a
T172 both in insulin-sensitive and insulin-
resistant myotubes (Figure 8e). These results are in accordance
with those of Jensen et al [29] which found that twitch-contraction
increased AMPK-a1 activity, but not AMPK-a2, in mouse skeletal
muscle. Altogether our findings demonstrate that Wnt signaling
increased glucose transport in both insulin-sensitive and insulin-
resistant myotubes through a differential activation of Akt2/
AS160 and AMPK-a1 pathways. Nevertheless, how BIO could
have a permissive effect on insulin action in insulin-resistant
myotubes remains to be determined.
As a switch in the differentiation potential of satellite cells to an
adipogenic phenotype could be partly responsible for intramyo-
cellular lipid deposition and insulin resistance in type 2 diabetes,
obesity and age-related sarcopenia, organe-selective modulation of
the Wnt/b-catenin pathway could contribute to fight intramuscu-
lar fat depots and improve insulin sensitivity in these pathologies.
For that purpose, the use of GSK-3b-specific inhibitors such as
BIO-derivatives may have practical applications in endocrine and
regenerative medicine. Nevertheless, as uncontroled canonical
Wnt signaling is a hallmark of cancer and other degenerative
diseases, understanding the ways in which the pathway is regulated
in skeletal muscle is of critical importance.
Materials and Methods
Ethics Statement
Animal experiments were conducted in accordance with the
Europeen convention STE 123 and the French decree 2001-286.
Animals and Regeneration Experiments
Regeneration experiments were conducted on crushed Extensor
Digitorum Longus (EDL) muscles of 2 month-old Sprague Dawley
male rats according to Bassaglia and Gautron [22]. After 2, 8 or 30
days, regenerated muscles were harvested and immediately frozen
in liquid nitrogen.
Primary Culture of Muscle Satellite Cells and Glucose
Uptake
Satellite cells from hind limb muscles were isolated and cultured
as previously described [45]. Cells were allowed to differentiate
onto growth factor-reduced Matrigel
TM-coated flasks (BD-Biosci-
ences) in DMEM medium containing horse serum, then serum
was totally removed to induce contraction. Glucose uptake assay
was performed in contracting myotubes using 2-deoxy-D-
[1-
3H]glucose (Amersham Pharmacia Biotech) as previously
described [45]. Results are expressed as means6SE. Statistical
significance was evaluated using ANOVA.
RNA Isolation and Semi-Quantitative RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen)
according to the supplier’s instructions. Gene expression was
measured using semi-quantitative RT-PCR. Sense and antisense
primers against mouse cDNAs were designed as follows: SREBP-
1c sense 59-GGAGCCATGGATTGCACATT-39; antisense 59-
GCTTCCAGAGAGGAGCCCAG-39. b-actin sense 59-TCAT-
GAAGTGTGACGTTGACATCC-39; antisense 59-GTAAAAC-
GCAGCTCAGTAACAGTC-39. MYHC-2 sense 59GGTACT-
TGGCGAGAGTGGAG-39; antisense 59-AGGGCCAGTGTT-
TCACATTC-39; PPAR-b sense 59-CTCAACATGGAATG-
TCGGGTGTGC-39; antisense 59-CTGATCTCGTTGTAGG-
GCGGCAGC-39; PPAR-c sense 59-ATGAAGACATTCCATT-
CACAAGAGC-39; antisense 59-ATAGTGGAAGCCAGATG-
CTTTATCC-39. Results were obtained from three to four
independent RNA samples from individual experiments, each
tested in triplicate.
Preparation of Protein Extracts and Plasma Membranes
Cytoplasmic and nuclear protein extracts were prepared using
the NE-PER
TM Nuclear and Cytoplasmic Extraction Reagents kit
(Pierce) according to the supplier’s instructions. Plasma mem-
branes were isolated according to a protocol previously described
[15].
Western Blot Analysis
Cells were immediately frozen in liquid nitrogen, scraped in ice-
cold RIPA buffer containing 1 mM PMSF, 2 mg/ml pepstatin A,
2.5 mg/ml benzamidine, 2 mg/ml leupeptin and 5 mg/ml aproti-
nin, then lysed for 2 hours at 4uC under rotational agitation. Total
cell lysates were recovered after centrifugation at 16,0006g for 30
minutes at 4uC to discard insoluble material. Proteins (30 mg) were
subjected to immunoblot analysis.
Antibodies
SREBP-1c was detected using a monoclonal antibody raised
against human SREBP-1 (NeoMarkers). Polyclonal antibodies
against MyoD, GAPDH, Wnt10b, GLUT4 and b-tubulin were
from Santa-Cruz Biotechnology. Rabbit monoclonal antibodies
against GSK-3b, Akt, P-Akt2
Ser473, P-Akt1
Thr308 and polyclonal
antibodies against P-GSK-3b
Ser9, P-AMPK-a1
Ser485, P-AMPK-
a
Thr172, P-PDK1
Ser241 and Lamine A/C were from Cell Signaling.
Rabbit monoclonal antibodies against AMPK-a1 and b-catenin
were from Epitomics. Monoclonal antibody against active b-
catenin was from Chemicon, as well as GLUT1 and AS160
antibodies. Antibody against P-AS160
Ser588 was from Symansis.
Monoclonal P-GSK-3b
Tyr216 antibody was from BD-Transduc-
tion Laboratories. Monoclonal antibodies against MyHC-Dev,
MyHC-2 were purchased from Sigma and anti-myogenin from
DAKO. Anti-FAS polyclonal antibody was a gift from Dr Dugail
(Paris).
siRNA Design
A target-specific 21-nt siRNA duplex against rat SREBP-1 was
designed as previously described [25] and purchased from
Dharmacon (Lafayette, CO). Wnt10b siRNA was a pool of 3
target-specific 20-25-nt siRNAs designed to silence mouse Wnt10b
gene (Santa-Cruz Biotechnology). Control siRNAs consisted of
scrambled sequences that will not lead to the specific degradation
of any known cellular mRNA.
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Myotubes were cultured in 6-well plates in DMEM without
serum, and antibiotics were removed the day before transfection.
SiRNA (60 pmoles/well) or pCAGGS plasmid containing the
mouse Wnt10b cDNA were transfected using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. Exper-
iments were performed 48 hours later.
Treatment of Myotubes with 6-Bromo-Indirubin 39Oxime
(BIO)
BIO, a cell-permeable, highly potent, selective, reversible and
ATP-competitive specific inhibitor of GSK-3a/b activity, was
provided by Drs A. Brivanlou and L. Meijer (The Rockefeller
University, New York). Myotubes were treated with 10
26 M BIO
for 48 hours, or with Me-BIO, an inactive form, as a control, then
2-deoxyglucose uptake was performed, or total protein lysates and
plasma membranes were prepared.
Intramyocellular Lipid Accumulation
Intramyocellular lipids were detected in myotubes using Oil
Red O staining according to Koopman et al [46]. Nuclei were
counterstained with DAPI (Molecular Probes), then fluorescence
was observed using a Nikon TS100 fluorescence microscope.
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